NG NGEN NervGen Pharma Corp. Loading... : Investor Sentiment and Bull/Bear Views

The author argues NervGen's NVG-291 targets the biological barrier to neural repair rather than masking symptoms, and cites the Phase 1b/2a CONNECT SCI trial meeting primary endpoints with an 825% increase in upper-body connectivity and ~3.7x greater hand-function improvement versus placebo. A $60M offering leaves roughly $61.1M in cash, which management says funds operations through the Phase 3 RESTORE primary readout expected in 1H 2028, removing near-term dilution risk. The catalyst path is Phase 3 enrollment completion in 2H 2027 and data in 1H 2028, with massive market potential if successful; the main risk is Phase 3 failure, since no approved drug repairs CNS damage this way.

The author argues NGEN's share price is a bargain relative to a peptide candidate in phase 3 that they believe will be transformative. They state they are increasing their position on Monday, making this a near-term bullish commitment tied to the phase 3 program. The main risk is clinical failure of the peptide program, which the author does not address.